MUC16 and pachyonychia congenita: Additionally, Liu et al.’s phase I study assessed the safety and pharmacokinetics of the antibody-drug conjugate DMUC5754A targeting MUC16 in patients with platinum-resistant ovarian cancer (OC) and unresectable pancreatic cancer (PC), observing significant tumor growth inhibition responses in ovarian cancer patients with high MUC16 expression (33).